Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is based on the methodology used by Tjalma and colleagues, and considered costs of drugs, healthcare professional time and consumables. We calculated intravenous drug costs for different body weights, and computed drug costs and healthcare costs to treat 100 patients with either trastuzumab formulation, assuming a binomial body weight distributio... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Reihe/Periodikum: | Pharmaceuticals, Vol 14, Iss 450, p 450 (2021) |
Verlag/Hrsg.: |
MDPI AG
|
Schlagwörter: | trastuzumab / biosimilar / intravenous / subcutaneous / HER2-positive breast cancer / drug costs / Medicine / R / Pharmacy and materia medica / RS1-441 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27310555 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.3390/ph14050450 |